Axsome Therapeutics (AXSM) announced that the U.S. Food and Drug Administration has accepted for filing the Company’s supplemental New Drug Application for AXS-05 for the treatment of Alzheimer’s disease agitation, and has granted the application Priority Review designation. The FDA has set a Prescription Drug User Fee Act target action date of April 30, 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics says AXS-12 NDA submission on track for January
- Strategic Acquisition and Pipeline Expansion Drive Buy Rating for Axsome Therapeutics
- Avenue Therapeutics announces Baergic Bio acquisition by Axsome
- Axsome enters agreement to obtain exclusive global rights to AZD7325
- Axsome Therapeutics price target raised to $202 from $200 at Mizuho